Oculogenital Syndrome Diagnosis and Treatment

Clinical Presentation and Diagnosis

• Chlamydial conjunctivitis typically presents as a follicular conjunctivitis with chemosis, papillary hypertrophy, and distinctive follicles on the bulbar conjunctiva and semilunar fold, according to the American Academy of Ophthalmology 1
• Gonococcal conjunctivitis presents with marked eyelid edema, significant purulent discharge, and preauricular lymphadenopathy; corneal infiltrates or ulcers may develop rapidly, as reported by the American Academy of Ophthalmology 1
• Both infections can be unilateral or bilateral, as noted by the American Academy of Ophthalmology 1
• Conjunctival specimens must contain conjunctival cells (not just exudate) collected from the everted eyelid using a dacron-tipped swab, as recommended by the Centers for Disease Control and Prevention 2
• For suspected chlamydial infection, the Centers for Disease Control and Prevention recommend culture, direct fluorescent antibody tests, enzyme immunoassays, or nucleic acid amplification tests 2
• For suspected gonococcal infection, the Centers for Disease Control and Prevention suggest a Gram stain showing intracellular gram-negative diplococci provides presumptive diagnosis; cultures should be obtained for definitive diagnosis 3
• The American Academy of Ophthalmology advises testing for both pathogens simultaneously as co-infection is common 4

Treatment

• The American Academy of Ophthalmology recommends ceftriaxone 250 mg IM single dose AND azithromycin 1 g orally single dose for gonococcal conjunctivitis in adults 4
• For cephalosporin-allergic patients, the American Academy of Ophthalmology suggests azithromycin 2 g orally single dose (though resistance concerns exist) 4
• The American Academy of Ophthalmology advises saline lavage of the infected eye to promote comfort and faster resolution 5
• If corneal involvement is present, the American Academy of Ophthalmology recommends adding topical antibiotics as for bacterial keratitis 5
• For neonates with gonococcal conjunctivitis, the Centers for Disease Control and Prevention recommend ceftriaxone 25-50 mg/kg IV or IM in a single dose (not to exceed 125 mg) 3, 4
• The American Academy of Ophthalmology recommends azithromycin 1 g orally in a single dose for chlamydial conjunctivitis in adults 4
• For pregnant women with chlamydial conjunctivitis, the American Academy of Ophthalmology suggests erythromycin or amoxicillin (doxycycline is contraindicated) 6
• For neonates with chlamydial conjunctivitis, the Centers for Disease Control and Prevention recommend erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days 2, 4

Management of Sexual Partners

• The Centers for Disease Control and Prevention advise that all sexual partners of patients with chlamydial or gonococcal conjunctivitis should be evaluated and treated 2, 3
• For gonococcal infection, the Centers for Disease Control and Prevention recommend treating mothers of infected infants and their sexual partners according to adult treatment guidelines 3
• The American Academy of Ophthalmology advises retesting approximately 3 months after treatment 4

Special Considerations

• The American Academy of Ophthalmology notes that sexual abuse must be considered as a cause of infection in preadolescent children 4
• Diagnosis of C. trachomatis or N. gonorrhoeae in preadolescent children should be documented by standard culture, as recommended by the American Academy of Ophthalmology 4
• The American Academy of Ophthalmology reports that gonococcal conjunctivitis can lead to corneal infection, scarring, perforation; systemic complications include septicemia, arthritis, meningitis 1, 3
• Chlamydial conjunctivitis can lead to corneal infiltrates, pannus, conjunctival scarring; associated with nasopharyngeal, genital, or pulmonary infection, as noted by the American Academy of Ophthalmology and the Centers for Disease Control and Prevention 1, 2
• Infants with chlamydial conjunctivitis may develop pneumonia (characterized by staccato cough, tachypnea, and bilateral diffuse infiltrates), according to the Centers for Disease Control and Prevention 2, 7

Follow-Up

• The American Academy of Ophthalmology recommends daily follow-up until resolution for gonococcal conjunctivitis, with visual acuity measurement and slit-lamp biomicroscopy at each visit 5
• For chlamydial conjunctivitis, the Centers for Disease Control and Prevention advise follow-up to determine treatment effectiveness; approximately 20% may require a second course of therapy 2
• The American Academy of Ophthalmology suggests advising return visit in 3-4 days if no improvement for other bacterial conjunctivitis 5

Management of Chlamydial Conjunctivitis in Neonates ≤ 30 Days

Epidemiology & Clinical Presentation

• Onset typically occurs 5–12 days after birth and is characterized by milder purulent discharge; maternal history of untreated chlamydia increases suspicion. (CDC MMWR Recommendations and Reports) [8][9]10

Diagnostic Approach

• Obtain conjunctival specimens from the everted eyelid using a dacron‑tipped swab, and submit for Gram stain and culture for Neisseria gonorrhoeae and Chlamydia trachomatis. (CDC MMWR Recommendations and Reports) 8

Systemic Antimicrobial Therapy

• Administer oral erythromycin base or ethylsuccinate at 50 mg/kg/day divided into four doses for 14 days; this is the only effective regimen for chlamydial neonatal conjunctivitis. (CDC MMWR Recommendations and Reports) [8][9]10
• Topical antibiotics are unnecessary when the appropriate systemic erythromycin regimen is given. (CDC MMWR Recommendations and Reports) [8][9]10

Anticipated Complications & Follow‑Up

• Infants with chlamydial conjunctivitis are at risk of developing chlamydial pneumonia between 1–3 months of age, presenting with a staccato cough, tachypnea, and diffuse bilateral infiltrates. (CDC MMWR Recommendations and Reports) [8][9]10
• Mandatory follow‑up after the 14‑day erythromycin course is essential to confirm clinical and microbiological resolution; a second course may be required in persistent cases. (CDC MMWR Recommendations and Reports) [8][9]10

Maternal and Partner Management

• A diagnosis of chlamydial conjunctivitis in the infant mandates evaluation and treatment of the mother and all sexual partners according to adult STD guidelines to prevent reinfection. (CDC MMWR Recommendations and Reports) [8][9]10

Prophylaxis Effectiveness

• Erythromycin 0.5 % ophthalmic ointment, while FDA‑approved for prophylaxis against gonococcal ophthalmia neonatorum, does not prevent chlamydial conjunctivitis or nasopharyngeal colonization. (CDC MMWR Recommendations and Reports) [8][9]10
• Neonatal ocular prophylaxis with silver nitrate, erythromycin, or tetracycline ointment does not prevent perinatal transmission of C. trachomatis from mother to infant. (CDC MMWR Recommendations and Reports) [8][9]10

Clinical Decision Rule

• Consider a chlamydial etiology for all infants < 30 days presenting with conjunctivitis, especially when there is a maternal history of untreated chlamydia. (CDC MMWR Recommendations and Reports) [8][9]10